drugset / Trial / NCT02766049

Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus

NCT02766049

Phase 1/2 Completed 19 enrolled University of Sao Paulo General Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study was to assess tolerability and safety of three different formulations of an anti-HIV immunotherapy based on autologous dendritic cells (DCs) pulsed with HIV chemically inactivated with Aldrithiol™-2 (AT-2). Patients were chronically infected with HIV, naïve for antiretroviral drugs. A possible immunological and virological favorable impact was also assessed.

Timeline

Start
2010-02
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DC10e6+HIV-AT2 Cell therapy 3e+06 cells
Subject DC10e6+HIV-AT2 Cell therapy 3e+07 cells
Subject autologous dendritic cells Cell therapy 3e+07 cells